Shares in Mylan (NSDQ:MYL) remained steady today after the pharmaceutical company missed expectations on Wall Street with its third quarter results. The Canonsburg, Penn.-based company posted profits of $88.3 million, or 16¢ per share, on sales of $2.99 billion for the 3 months ended Sept. 30, for bottom-line growth of 172% on sales loss of -2% […]
Mylan
Report: Seven deaths from EpiPen failures this year
Defective EpiPens have been cited in seven deaths this year so far, according to reports made to the FDA and obtained by Bloomberg News. During the same period, the FDA has received 228 reports of EpiPen failures and at least 35 people were hospitalized as a result of those failures. Failure reports for Mylan‘s (NSDQ:MYL) life-saving […]
Sanofi files patent infringement suit against Mylan over insulin pen
Sanofi (NYSE:SNY) filed a patent infringement suit against Mylan (NSDQ:MYL) yesterday in the U.S. District Court of New Jersey, alleging that the EpiPen-maker infringed upon 18 patents covering Sanofi’s Lantus insulin glargine injection and SoloStar pen. The suit was triggered by a notice from Mylan in mid-September, Sanofi said. Mylan told the insulin-maker that it had […]
Mylan: Allergan’s legal move with tribe reveals “duplicitousness” towards patent system
Allergan (NYSE:AGN) was dealt a major blow yesterday after a Texas judge ruled that claims to a number of patents for its dry eye drug, Restasis, were invalid due to obviousness. The ruling opens the door for generic versions of the drug that accounted for nearly 10% of Allergan’s revenue last year. The decision came […]
Texas judge rules Allergan’s Restasis patents invalid
U.S. judge William Bryson ruled that patents covering Allergan‘s (NYSE:AGN) Restasis medicine are invalid on the grounds of obviousness, driving the company’s shares down more than -6% in afternoon trading today. The decision, made in a Texas federal court, is part of an ongoing case between Allergan and generic drugmakers like Mylan (NSDQ:MYL) and Teva Pharmaceuticals […]
Allergan settles Restasis patent challenge after moving patents to Native American tribe
Allergan (NYSE:AGN) said yesterday that it inked a deal with InnoPharma to settle a patent challenge over Allergan’s dry eye drug, Restasis. InnoPharma is one of four companies challenging Allergan’s patents to its eye drop product. The group also includes Mylan (NSDQ:MYL), Teva Pharmaceuticals (NYSE:TEVA) and Akorn Inc. (NSDQ:AKRX) – all of which are challenging the Restasis patents in […]
Report: Mylan to pony up $20m to Massachusetts in EpiPen settlement
Mylan (NSDQ:MYL) is slated to pay $20.3 million to the Massachusetts Medicaid program to resolve claims that it underpaid the program by misclassifying its EpiPen device, according to attorney general Maura Healey. “Mylan knowingly misrepresented this drug to MassHealth in order to underpay on rebates and make a profit at the expense of our state,” Healey […]
Ocular continues personnel shakeup with new CMO | Personnel Moves – Sept. 13, 2017
After Ocular Therapeutix‘s (NSDQ:OCUL) founder & CEO, Amar Swahney, stepped down earlier this year, pharma executive Antony Mattessich stepped in to assume the corner office. He signaled some major changes to the company’s business strategy in a call with analysts last month, including an attempt to ‘aggressively seek new partnerships’ and ‘enhance [the company’s] credibility’. As […]
EpiPen manufacturer is hit with FDA warning letter
Mylan (NSDQ:MYL) today made public a warning letter that the FDA sent to EpiPen manufacturer, Meridian Medical Technologies. In the letter, the regulatory agency summarizes “significant violations of current good manufacturing practice requirements for combination products”, including issues relating to quality control procedures, product complaint resolution and design verification. Among other products, Meridian manufactures Mylan’s EpiPen […]
Impax settles ‘fax-blasting’ class action suit over EpiPen alternative
Impax Laboratories (NSDQ:IPXL) will pony up $4.8 million to settle claims that it sent blasts of unsolicited faxes to Family Medicine Pharmacy advertising its epinephrine auto-injector, according to a document filed in a Alabama federal court this week. The Alabama-based pharmacy filed the proposed class action suit against Impax in January, alleging that the pharmaceutical company […]
